Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Research & Development (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Research & Development for 7 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 31.61% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.1 million through Dec 2025, down 11.49% year-over-year, with the annual reading at $56.1 million for FY2025, 11.49% down from the prior year.
  • Research & Development for Q4 2025 was $15.4 million at Fulcrum Therapeutics, up from $14.3 million in the prior quarter.
  • The five-year high for Research & Development was $25.0 million in Q2 2022, with the low at $11.7 million in Q4 2024.
  • Average Research & Development over 5 years is $16.9 million, with a median of $17.2 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 43.97% in 2022, then plummeted 38.35% in 2024.
  • Over 5 years, Research & Development stood at $18.9 million in 2021, then fell by 1.83% to $18.6 million in 2022, then rose by 2.33% to $19.0 million in 2023, then tumbled by 38.35% to $11.7 million in 2024, then soared by 31.61% to $15.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $15.4 million, $14.3 million, and $13.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.